Natera developed a personalized, tumor-informed approach for molecular residual disease (MRD) detection by using Signatera after surgery to evaluate the need for adjuvant chemotherapy and potentially avoid unnecessary treatment. For more information, you refer to https://natera.showpad.com/share/tjYrvLiWX9XKSTyjfJJL3
1. Complying to agreed requirements
2. Complying to agreed time plan, if applicable
3. Quality of delivered services compared with the required Specifications
4. Steps followed to provide the service
5. Cooperation of FutureLab employees
6. Responsiveness to requirements
7. Employees’ communication skills
8. Commitment to confidentiality agreement
9. Please share with us your positive and negative comments and opinions regarding any notes concerning our service
10. Any other suggestions or recommendations
Something went wrong while submitting your application
Your application has been submitted successfully
Your review has been sent successfully.
Something went wrong while subscribing
You've subscribed successfully to our newsletter